Jean Holloway - Artivion Insider
| AORT Stock | USD 25.56 2.29 8.22% |
Insider
Jean Holloway is Senior Vice President Chief Compliance Officer, General Counsel, Secretary of Artivion since 2016.
| Age | 63 |
| Tenure | 9 years |
| Address | 1655 Roberts Boulevard N.W., Kennesaw, GA, United States, 30144 |
| Phone | 770 419 3355 |
| Web | https://artivion.com |
Jean Holloway Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jean Holloway against Artivion stock is an integral part of due diligence when investing in Artivion. Jean Holloway insider activity provides valuable insight into whether Artivion is net buyers or sellers over its current business cycle. Note, Artivion insiders must abide by specific rules, including filing SEC forms every time they buy or sell Artivion'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jean Holloway over two months ago Disposition of 4035 shares by Jean Holloway of Artivion at 30.0 subject to Rule 16b-3 | ||
Jean Holloway over three months ago Disposition of 3167 shares by Jean Holloway of Artivion at 26.5538 subject to Rule 16b-3 | ||
Jean Holloway over six months ago Disposition of 3167 shares by Jean Holloway of Artivion at 26.5538 subject to Rule 16b-3 | ||
Jean Holloway over six months ago Disposition of 979 shares by Jean Holloway of Artivion at 23.785 subject to Rule 16b-3 |
Artivion Management Efficiency
The company has return on total asset (ROA) of 0.0307 % which means that it generated a profit of $0.0307 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0479) %, meaning that it created substantial loss on money invested by shareholders. Artivion's management efficiency ratios could be used to measure how well Artivion manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.09 in 2025. Return On Capital Employed is likely to drop to 0.01 in 2025. At this time, Artivion's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 956.8 M in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 43.7 M in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jared Oasheim | CVRx Inc | 41 | |
| Heather Brennan | Establishment Labs Holdings | N/A | |
| Chi Nguyen | Neuropace | 47 | |
| Mark CPA | Treace Medical Concepts | 55 | |
| MBA BS | Sight Sciences | N/A | |
| S Mansbach | Avanos Medical | N/A | |
| Sri Radhakrishnan | Pulmonx Corp | N/A | |
| Mark Saxton | Neuropace | 59 | |
| Rebecca Kuhn | Neuropace | 64 | |
| John Treace | Treace Medical Concepts | 53 | |
| Kerr Holbrook | Avanos Medical | 58 | |
| Michelle Scharfenberg | Avanos Medical | N/A | |
| Jaime Frias | Treace Medical Concepts | 62 | |
| David Crawford | Avanos Medical | N/A | |
| Derrick Sung | Pulmonx Corp | 51 | |
| Salvador Dada | Establishment Labs Holdings | 43 | |
| Andre Marquette | Neuropace | N/A | |
| Daniel Owens | Treace Medical Concepts | 53 | |
| Gregory Davault | Axogen Inc | 56 | |
| Paul Verrastro | CVRx Inc | 61 | |
| Bradley JD | Axogen Inc | 54 | |
Management Performance
| Return On Equity | -0.0479 | ||||
| Return On Asset | 0.0307 |
Artivion Leadership Team
Elected by the shareholders, the Artivion's board of directors comprises two types of representatives: Artivion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Artivion. The board's role is to monitor Artivion's management team and ensure that shareholders' interests are well served. Artivion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Artivion's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Bevevino, Independent Director | ||
| Jeffrey Burbank, Lead Independent Director | ||
| Jean Holloway, Senior Vice President Chief Compliance Officer, General Counsel, Secretary | ||
| Jon Salveson, Independent Director | ||
| Andrew Green, Vice President - Regulatory Affairs | ||
| Thomas Ackerman, Independent Director | ||
| Rochelle Maney, Vice President - Global Quality Assurance | ||
| Scott Capps, Vice President - Clinical Research | ||
| Marna Borgstrom, Independent Director | ||
| Matthew Getz, Vice President - Human Resources | ||
| James Bullock, Independent Director | ||
| Jean Esq, General VP | ||
| D Lee, Chief Financial Officer, Chief Operating Officer, Executive Vice President | ||
| CPA CPA, VP Officer | ||
| James Mackin, Chairman of the Board, President, Chief Executive Officer, Director | ||
| Anthony Semedo, Independent Director | ||
| Dennis Maier, Vice President - Operations | ||
| Joshua Wells, Sr Devel | ||
| Marshall Stanton, Senior Vice President Clinical Research and Chief Medical Officer | ||
| Marshall MD, Senior Officer | ||
| Robert Thomson, Vice Development | ||
| Amy CPA, VP Officer | ||
| Florian Tyrs, Vice Operations | ||
| Lance CPA, Executive CFO | ||
| F Barthold, Vice President - Research and Development | ||
| Amy Horton, Chief Accounting Officer, Vice President | ||
| John Davis, Senior Vice President - Global Sales and Marketing |
Artivion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Artivion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0479 | ||||
| Return On Asset | 0.0307 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 1.47 B | ||||
| Shares Outstanding | 41.92 M | ||||
| Shares Owned By Insiders | 5.50 % | ||||
| Shares Owned By Institutions | 92.13 % | ||||
| Number Of Shares Shorted | 3.8 M | ||||
| Price To Book | 3.83 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Artivion Stock Analysis
When running Artivion's price analysis, check to measure Artivion's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artivion is operating at the current time. Most of Artivion's value examination focuses on studying past and present price action to predict the probability of Artivion's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artivion's price. Additionally, you may evaluate how the addition of Artivion to your portfolios can decrease your overall portfolio volatility.